The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study

• DOI: 10.1016/j.jsps.2023.05.006
• Publication Date: 2023-05-23T13:41:13Z
• Authors: Ohoud Aljuhani; Ghazwa B. Korayem; Ali F. Altebainawi; Meshal S. Alotaibi; Noura A. Alrakban; Ragia H. Ghoneim; Ramesh Vishwakarma; Abdulrahman I. Al...; Shmeylan Al Harbi; Jawaher Gramish; Dahlia M. Almutairi; Ghada Alqannam; Faisal F. Alamri; Abdullah F. Alharthi; Mashael Alfaifi; Abdullah Al Amer; Abeer A. Alenazi; Norah Bin Aydan; Mai Alalawi; Khalid Al Sulaiman
• Keywords: Oseltamivir; Clinical endpoint

Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, evidence about using oseltamivir critically ill severe COVID-19 remains scarce. This study aims to evaluate effectiveness and safety COVID-19.This multicenter, retrospective cohort includes adult admitted intensive care unit (ICU). Patients were categorized into two groups based on use within 48 hours ICU admission (Oseltamivir vs. Control). The primary endpoint was viral load clearance.A total 226 matched their propensity score. time clearance shorter who received (11 16 days, p = 0.042; beta coefficient: -0.84, 95%CI: (-1.33, 0.34), 0.0009). Mechanical ventilation (MV) duration also (6.5 8.5 0.02; -0.27, 95% CI: [-0.55,0.02], P 0.06). In addition, had lower odds hospital/ventilator-acquired pneumonia (OR:0.49, CI:(0.283,0.861), 0.01). On other hand, there no significant differences between 30-day in-hospital mortality.Oseltamivir associated faster MV without concerns patients.